This constellation is consistent with the results of a recent IPD level meta-analysis that patients with HAVCR2 mutations, both homozygous and heterozygous, manifested with SPTCL with or without HLH/HLH-like systemic illnesses earlier than those with HAVCR2 wild-type [7]. The gene discussed is HAVCR2; the disease is hemophagocytic syndrome.